HemoTimes uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 10, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced updated clinical data in patients treated in the Company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant, for the treatment of patients with severe and moderately severe hemophilia B.